InventisBio | Evaluate

Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.

Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.

October 06, 2020

Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.

February 19, 2020

As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.

Evaluate